<DOC>
	<DOCNO>NCT02091752</DOCNO>
	<brief_summary>The aim study assess efficacy safety restart ruxolitinib treatment interruption due loss response and/or adverse event .</brief_summary>
	<brief_title>A Phase II Study Re-treatment Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due Loss Response and/or Adverse Event ( ReTreatment Trial )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Confirmed diagnosis PMF , PPV MF PETMF , irrespective JAK2 mutational status accord 2008 revise International Standard Criteria Peripheral blast count &lt; 10 % Requires therapy MF opinion investigator Received prior monotherapy treatment ruxolitinib least 12 consecutive week experience treatment interruption lossof response adverse event Patients adhere Screening phase assessment undergoing ruxolitinibfree washout period minimum 1 week maximum 8 week ECOG performance status 0 , 1 , 2 , 3 Adequate bone marrow function Written inform consent Patients initially respond ( primary resistance ) ruxolitinib therapy Patients underwent splenectomy spleen radiation Patients currently schedule bone marrow transplant Patients discontinue ruxolitinib &lt; 14 day prior screen Patients able receive start dose ruxolitinib least 15 mg total daily dose Leukemic transformation Inadequate renal function Presence clinically meaningful active bacterial , fungal , parasitic viral infection require therapy Previous history Progressive Multifocal Leukoencephalopathy ( PML ) Clinically significant cardiac disease significant concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>